Vimarsana
Biggest News Aggregation in the World

Page 6 - Jonathan Solomon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Solomon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Solomon Today - Breaking & Trending Today

BiomX Inc. (AMEX:PHGE) Q4 2022 Earnings Call Transcript - Vimarsana News

BiomX Inc. (AMEX:PHGE) Q4 2022 Earnings Call Transcript

Operator: Good morning, and welcome to the BiomX Full Year 2022 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode.

Mumbai: Terrorists of 26/11 attacks should be brought to justice, says Israel Knesset speaker - Vimarsana News

Mumbai: Terrorists of 26/11 attacks should be brought to justice, says Israel Knesset speaker

One hundred and sixty six people died and over 300 were injured in the terror attack that included people from different nationalities.

Phage cocktail BX004 seen to lower P. aeruginosa in small CF trial | Part 2 of ongoing study to test nebulized therapy in more patients - Vimarsana News

Phage cocktail BX004 seen to lower P. aeruginosa in small CF trial | Part 2 of ongoing study to test nebulized therapy in more patients

BX004, a phage cocktail by BiomX, safely reduced the number of Pseudomonas aeruginosa bacteria in the lungs of CF patients in a small trial.

BiomX To Present at H.C. Wainwright 1st Annual Investor - Vimarsana News

BiomX To Present at H.C. Wainwright 1st Annual Investor

NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company...

BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage - Vimarsana News

BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

29.11.2022 - NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) - BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, ...